PCRX Pacira BioSciences, Inc. Common Stock
XNAS
36.46
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
PCRX
$36.46
—
What changed
Recent filings, trades and movesKey stats
$36.46
- 52-Week Range
- $18.80 – $36.66
- YTD
- +49.06%
- IV Rank (30D)
- 66.51
- Straddle Price
- $6.60
- P/C Vol Ratio
- 0.54
- Market Cap
- $1.5B
- Open
- $36.44
- Day Range
- $36.44 – $36.47
- Volume
- 237,345
- Prev Close
- $36.43
Fair Value
MODEL: NEUTRAL
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.90% |
| Beta vs SPY | 0.85 |
| Cost of Equity (CAPM) | 9.16% (VRP-adj) |
| WACC | 8.51% |
| Volatility Risk Premium | -91.2pp (IV − HV30) |
| Effective Tax Rate | 17.1% |
| Rev. Growth (YoY, DCF input) | +7.2% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.07 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $0.2B |
| Return on Equity (TTM) | 2.2% |
| Book / Price | 45.8% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 79.2% |
| FCF Margin (TTM) | 24.1% |
| Debt / Equity | 0.54 |
| Quality Score | 3/6 — normal (10y DCF) |
| Market-Implied Growth | -8.0% (reverse-DCF on current price) |
| SMA 50 | $30.17 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $36.38 |
| Bollinger Width / SMA20 | 0.4% (drives anchor stability) |
| Net Debt | $0.2B |
| Market Cap | $1B |
Peers used for multiples: OGN, SUPN, VTRS
(filtered from 8 ETF-co-members; sector bias active)
60-Day Conviction
20%
20-Day Fair Value
≈ by Dec 8, 2026
$36.59
α +0.4%
rank 79%
conviction
27%
40-Day Fair Value
≈ by Jan 6, 2027
$36.36
α -0.3%
rank 79%
conviction
11%
60-Day Fair Value
≈ by Feb 4, 2027
$36.20
α -0.7%
rank 79%
conviction
20%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $96.66 | 25% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | $29.35 | 7% | median 11.8× · 3 peers |
| Peer P/B | $25.68 | 10% | median 1.5× · 3 peers |
| Peer P/S | $29.37 | 10% | median 1.5× · 3 peers |
| Market Anchor (SMA50) | $30.17 | 49% | stability 100% (BB-width) |
| Options Expected (B-L 30d) | $37.06 | 0% | 5 strikes · skew +1.29 |
As of 2026-11-09 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $1.5B
- Employees
- 829
- List Date
- 2011-02-03
- CIK
- 0001396814
- Last Earnings
- Aug 4 before open · +2.6% vs ±11.0% expected
- Headquarters
- Brisbane, CA
- Homepage
- https://www.pacira.com
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold …
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 11.41% | 2.57% | 1.06% | 1.84% | 43.64% | -16.03% | 7.42% |
| Feb | 5.03% | 6.89% | 4.93% | -6.47% | -6.60% | 3.25% | 1.17% |
| Mar | -3.40% | 12.78% | -5.92% | 1.25% | 8.23% | 6.20% | 3.19% |
| Apr | -9.73% | -4.26% | 9.52% | -9.95% | 11.76% | 11.85% | 1.53% |
| May | -1.32% | -14.90% | -18.39% | 12.54% | -3.40% | -4.99% | -5.08% |
| Jun | -3.08% | -8.12% | 5.34% | -7.38% | -8.92% | 10.50% | -1.94% |
| Jul | -1.72% | -2.23% | -9.33% | -27.44% | -9.29% | 6.58% | -7.24% |
| Aug | 0.12% | -6.59% | -1.94% | -25.01% | 20.84% | -3.79% | -2.73% |
| Sep | -5.55% | 1.78% | -13.65% | -0.86% | -5.33% | -5.36% | -4.83% |
| Oct | -8.25% | -6.01% | -5.36% | 8.50% | -15.39% | 45.50% | 3.16% |
| Nov | -2.10% | -8.01% | -3.64% | 2.05% | 6.22% | 0.15%* | -0.89% |
| Dec | 12.91% | -18.25% | 21.32% | 5.78% | 9.20% | -- | 6.19% |
| Total | -8.02% | -39.19% | -20.21% | -42.81% | 45.41% | 52.89% | -1.99% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $36.38
SMA 50: $30.38
SMA 200: $25.33
Current: $36.46
EMA 12: $36.16
EMA 26: $34.47
MACD: 1.6932 | Signal: -0.3953
BULLISH
ADX (14): 66.22
STRONG TREND
+DI: 52.69
−DI: 6.41
Momentum Oscillators
RSI (14): 83.38
OVERBOUGHT
Stoch %K: 82.36
Stoch %D: 69.43
Williams %R: -6.25
Volume & Volatility
BB Upper: $36.46
BB Lower: $36.31
OVERBOUGHT
OBV: 53,045,086
Vol SMA 20: 1,118,279
Vol ROC: -62.24%
ATR: $0.36
True Range: $0.04
HV 20: 1.7%
HV 30: 107.1%
HV 60: 78.5%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall Assessment: NEUTRAL (Confidence Level: 6/10)
Key Drivers: Positive news headlines, oversold RSI, bullish MACD
Primary Risks: Low volatility, mixed signals from technical indicators
2-3 Sentence Investment Thesis: Pacira BioSciences' stock appears to be a short-term buy candidate due to its oversold condition and positive recent news sentiment. However, the low volatility and mixed signals from technical indicators suggest caution is warranted.
Recent News Sentiment Impact: The news headlines have been predominantly positive, with two earnings-related announcements and a real-world data presentation showing lower total healthcare costs in outpatient procedures. This has contributed to the bullish tone in the options market.
Technical Analysis
Trend Direction: Short-term: DOWN (1-4 weeks), Medium-term: NEUTRAL (1-3 months), Long-term: UP (3-12 months)
Support/Resistance Levels: $23.59 (SMA 200), $25.52 (SMA 20), $28.04 (Upper Bollinger Band)
Momentum Signals:
-
RSI Interpretation: Oversold (33.97)
-
MACD Signal: Bullish
-
Bollinger Bands Position: Oversold
-
Volume Analysis: Volume SMA 20: 668805.50, On-Balance Volume (OBV): 21043968.16, Volume Rate of Change: -19.39%
News & Sentiment Analysis
Recent Headlines Summary: Positive earnings-related announcements and real-world data presentation.
Sentiment Assessment: Aggregate sentiment is POSITIVE due to the majority of news headlines being positive.
Catalyst Identification: Upcoming earnings release (August 4, 2026).
Market Narrative: The recent news sentiment aligns with the bullish MACD signal, suggesting a potential short-term bounce. However, the low volatility and mixed signals from technical indicators suggest caution is warranted.
Risk & Volatility Assessment
Beta Interpretation: Low risk relative to market (beta: 0.35).
Volatility Regime: Current volatility level is relatively low compared to historical levels.
Options Market Signals: IV rank: 10.4% (Low), Put/Call Volume Ratio: 0.13 (Bullish sentiment).
Downside Protection: Support levels at $23.59 (SMA 200) and $25.52 (SMA 20).
Market Context & Positioning
Sector Performance: Pacira BioSciences is performing relatively well within the healthcare sector.
Institutional Activity: Mixed signals from institutional investors, with some institutions increasing their exposure to the stock.
Correlation Analysis: The stock's correlation with the market is low (R-squared: 0.12).
Relative Valuation: Pacira BioSciences appears to be trading within its typical range.
Key Levels & Action Items
Critical Price Levels: $23.59 (SMA 200), $25.52 (SMA 20), and $28.04 (Upper Bollinger Band) are key support and resistance levels to monitor.
Breakout/Breakdown Levels: A break above $28.04 or below $23.59 could trigger significant moves in the stock price.
Time-Sensitive Catalysts: Upcoming earnings release (August 4, 2026).
Risk Management: Consider setting a stop-loss level at $22.90 and position sizing to manage risk.
Note: The analysis is based on the provided data and may not reflect the actual performance of the stock.
Generated
News
All PCRX news →
Earnings History
26 of 26 under expected move
Avg Expected Move
13.07%
Avg Actual Move
3.33%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-01-07 | After-Close | 4.91% | 3.65% | 0.74x | Within |
| 2021-05-04 | After-Close | 9.01% | 0.39% | 0.04x | Within |
| 2021-07-13 | After-Close | 8.63% | 0.22% | 0.03x | Within |
| 2021-11-03 | After-Close | 5.99% | 0.20% | 0.03x | Within |
| 2022-01-06 | After-Close | 10.70% | 1.15% | 0.11x | Within |
| 2022-04-12 | After-Close | 15.87% | 2.44% | 0.15x | Within |
| 2022-06-14 | After-Close | 23.31% | 5.94% | 0.25x | Within |
| 2022-08-03 | After-Close | 20.21% | 0.54% | 0.03x | Within |
| 2022-12-13 | After-Close | 13.06% | 1.32% | 0.10x | Within |
| 2023-05-03 | After-Close | 8.37% | 0.05% | 0.01x | Within |
| 2023-08-02 | After-Close | 9.07% | 5.56% | 0.61x | Within |
| 2023-11-02 | After-Close | 10.28% | 6.34% | 0.62x | Within |
| 2024-01-04 | After-Close | 6.11% | 5.71% | 0.93x | Within |
| 2024-02-29 | After-Close | 11.37% | 2.89% | 0.25x | Within |
| 2024-05-07 | After-Close | 18.41% | 11.84% | 0.64x | Within |
| 2024-07-30 | Pre-Market | 38.32% | 4.00% | 0.10x | Within |
| 2024-11-06 | Pre-Market | 10.27% | 2.26% | 0.22x | Within |
| 2025-01-10 | After-Close | 10.30% | 2.37% | 0.23x | Within |
| 2025-02-27 | After-Close | 13.59% | 5.24% | 0.39x | Within |
| 2025-05-08 | Pre-Market | 9.63% | 1.07% | 0.11x | Within |
| 2025-08-05 | After-Close | 12.31% | 0.62% | 0.05x | Within |
| 2025-11-06 | Pre-Market | 16.48% | 3.43% | 0.21x | Within |
| 2026-01-08 | After-Close | 17.58% | 9.57% | 0.54x | Within |
| 2026-02-26 | After-Close | 13.06% | 3.01% | 0.23x | Within |
| 2026-04-30 | After-Close | 11.97% | 4.12% | 0.34x | Within |
| 2026-08-04 | Pre-Market | 10.96% | 2.60% | 0.24x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
PCRX Options Activity & IV Rank
PCRX IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 65.9%
7-DTE IV: 65.9%
Expected Move: $6.60
7-DTE Move: $6.58
Days to Exp: 39 (2026-12-18)
Options Flow · All expiries
Call Volume: 289
Put Volume: 157
P/C Volume: 0.543
BULLISH
Call OI: 3,252
Put OI: 2,196
P/C OI: 0.675
Total OI: 5,448
ATM Options Pricing
ATM Call: $5.00
ATM Put: $1.60
Call %: 13.7%
Put %: 4.4%
Chain Summary
Chain Volume: 446
Chain OI: 5,448
Last Updated: 11/9/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
HIGH γ vs HISTORY
Estimated net dealer gamma is at the 100th percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
100%
vs own history
GEX tilt
+0.46
OI-weighted, today
Vanna tilt
+1.00
δ-sensitivity to IV
Charm tilt
-0.99
δ-decay vs time
Vanna tilt +1.00: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.99: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 8 ATM contracts, 4k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)11.8LowNov 9
IV Rank (30 DTE)66.5MediumNov 9
Straddle Price (30 DTE)$6.60Nov 9
Beta Analysis
Risk Metrics
Beta: 0.0718
Alpha: 63.70%
Correlation: 0.0174
R-Squared: 0.0%
Stock Volatility: 57.0%
Market Volatility: 13.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own PCRX
4 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $44.0M | #378 of 3138 | -5.0% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $6.0M | #1943 of 3716 | +312.3% | 13F | |
| Citadel Hedge fund Ken Griffin | $4.1M | #2253 of 6285 | -79.7% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $27K | #3630 of 4729 | -30.1% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
PCRX Institutional Ownership (13F)
Filings for 2026-06-30 · 111 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 42,677,750 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
3 filers$827.06K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $449.05K | 54.29% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $370.40K | 44.79% | 2026-06-30 |
| 3 | GROUP ONE TRADING LLC Custodian | $7.61K | 0.92% | 2026-06-30 |
2 filers$225.73K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $220.72K | 97.78% | 2026-06-30 |
| 2 | Simplex Trading, LLC Custodian | $5.01K | 2.22% | 2026-09-30 |
PCRX Insider Trading (Form 4)
Latest: 2026-11-03Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-11-03 | Shawn Cross | Chief Financial Officer | Tax (F) | −9,540 | $36.39 | -$347.2K | EDGAR |
| 2026-10-09 | Lauren Riker | Senior Vice President, Finance | Mixed Exer +6,000 · Sell −6,000 |
— | $34.34 | -$23.8K | EDGAR |
| 2026-08-18 | Jonathan Slonin | Chief Medical Officer | Sell (S) | −3,040 | $23.23 | -$70.6K | EDGAR |
| 2026-06-12 | Lauren Riker | Senior Vice President, Finance | Sell (S) | −6,115 | $23.50 | -$143.7K | EDGAR |
| 2026-06-12 | Marcelo Bigal | Director | Award (A) | +6,405 | — | EDGAR | |
| 2026-06-12 | Michael J. Yang | Director | Award (A) | +6,405 | — | EDGAR | |
| 2026-06-12 | Mark Froimson | Director | Award (A) | +6,405 | — | EDGAR | |
| 2026-06-12 | Alethia Young | Director | Award (A) | +6,405 | — | EDGAR | |
| 2026-06-12 | Laura Brege | Director | Award (A) | +6,405 | — | EDGAR | |
| 2026-06-12 | Samit Hirawat | Director | Award (A) | +6,405 | — | EDGAR | |
| 2026-06-12 | Christopher Christie | Director | Award (A) | +6,405 | — | EDGAR | |
| 2026-06-12 | Thomas G Wiggans | Director | Grant (A) | +32,675 opt | — | EDGAR | |
| 2026-06-05 | Jonathan Slonin | Chief Medical Officer | Tax (F) | −4,728 | $22.32 | -$105.5K | EDGAR |
| 2026-06-05 | Lauren Riker | Senior Vice President, Finance | Tax (F) | −3,187 | $22.32 | -$71.1K | EDGAR |
| 2026-06-05 | Kristen Williams | Chief Administrative Officer | Mixed Tax −8,528 · Sell −10,259 |
−18,787 | $22.29 | -$418.8K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
PCRX Insider Holdings
16 insiders · @ $36.46
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Frank D. Lee | Chief Executive Officer | 660,830 | $24.09M | $100.0K | 7 | 2026-02-13 |
| 2 | Jonathan Slonin | Chief Medical Officer | 216,383 | $7.89M | -$628.0K | 22 | 2026-08-18 |
| 3 | Kristen Williams | Chief Administrative Officer | 167,062 | $6.09M | -$14.21M | 37 | 2026-06-05 |
| 4 | Daryl Gaugler | Chief Operating Officer | 115,443 | $4.21M | -$327.8K | 11 | 2025-01-06 |
| 5 | Brendan Teehan | Chief Commercial Officer | 100,934 | $3.68M | $0 | 4 | 2026-02-13 |
| 6 | Shawn Cross | Chief Financial Officer | 95,801 | $3.49M | -$1.52M | 8 | 2026-11-03 |
| 7 | Lauren Riker | Senior Vice President, Finance | 62,284 | $2.27M | -$5.77M | 53 | 2026-10-09 |
| 8 | Mark A. Kronenfeld | Director | 31,065 | $1.13M | -$331.5K | 20 | 2026-03-19 |
| 9 | Laura Brege | Director | 30,120 | $1.10M | -$1.24M | 21 | 2026-06-12 |
| 10 | Mark Froimson | Director | 26,541 | $967.7K | -$103.4K | 17 | 2026-06-12 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
PCRX Board & Officers
As of SEC filings through Nov 3, 2026Directors 11
- Laura Brege · since Jun 2, 2011
- Mark A. Kronenfeld · since Jun 12, 2013
- Mark Froimson · since Jun 14, 2017
- Christopher Christie · since Sep 18, 2019
- Abraham Ceesay · since Oct 6, 2023
- Alethia Young · since Oct 6, 2023
- Marcelo Bigal · since Oct 6, 2023
- Michael J. Yang · since Oct 6, 2023
- Frank D. Lee · since Jan 2, 2024
- Samit Hirawat · since Jan 27, 2026
- Thomas G Wiggans · since Jun 9, 2026
Officers 6
- Frank D. Lee · Chief Executive Officer · since Jan 2, 2024
- Lauren Riker · Senior Vice President, Finance · listed since Jan 2022
- Shawn Cross · Chief Financial Officer · since Oct 21, 2024
- Kristen Williams · Chief Administrative Officer · listed since Aug 2019
- Jonathan Slonin · Chief Medical Officer · listed since Dec 2023
- Brendan Teehan · Chief Commercial Officer · since Jan 21, 2025
Changes in the last 10 years (35)
| Jun 9, 2026 | Thomas G Wiggans became a director |
| Jan 27, 2026 | Samit Hirawat became a director |
| Jan 28, 2025 | The company announced the departure of Paul J Hastings from the board in an SEC filing |
| Jan 21, 2025 | Brendan Teehan became Chief Commercial Officer |
| Oct 21, 2024 | Shawn Cross became Chief Financial Officer |
| Jun 11, 2024 | The company announced the departure of Gary W Pace from the board in an SEC filing |
| Feb 26, 2024 | The company announced the departure of Charles A. Reinhart III as Chief Financial Officer in an SEC filing |
| Jan 2, 2024 | Frank D. Lee became a director |
| Jan 2, 2024 | Frank D. Lee became Chief Executive Officer |
| Dec 7, 2023 | Jonathan Slonin listed as Chief Medical Officer (previously Chief Clinical Officer) in SEC filings |
| Oct 6, 2023 | Michael J. Yang became a director |
| Oct 6, 2023 | Marcelo Bigal became a director |
| Oct 6, 2023 | Alethia Young became a director |
| Oct 6, 2023 | Abraham Ceesay became a director |
| Sep 20, 2023 | The company announced the departure of David M Stack from the board in an SEC filing |
| Sep 20, 2023 | The company announced the departure of David M Stack as CEO and Chairman in an SEC filing |
| Mar 18, 2023 | The company announced the departure of Yvonne Greenstreet from the board in an SEC filing |
| Mar 14, 2023 | Ronald J. Ellis Jr. became Chief Strategy Officer |
| May 4, 2022 | Daryl Gaugler became Chief Operating Officer |
| Jan 10, 2022 | Lauren Riker listed as Senior Vice President, Finance (previously Vice President, Finance) in SEC filings |
| Dec 7, 2021 | Anthony Molloy became Chief Lgl & Compliance Officer |
| Aug 5, 2021 | Roy Winston listed as Chief Medical Officer (previously Chief Clinical Officer) in SEC filings |
| Jul 20, 2021 | Jonathan Slonin became Chief Clinical Officer |
| Jun 8, 2021 | Max Reinhardt listed as President, Rest of World (previously President) in SEC filings |
| Jun 8, 2021 | Dennis McLoughlin listed as Chief Customer Officer (previously Chief Commercial Officer) in SEC filings |
| Jun 8, 2021 | Charles Anthony Laranjeira listed as Chief Technical Officer (previously SVP, Technical Operations) in SEC filings |
| May 1, 2020 | Donald C. Manning became Chief Medical Officer |
| Sep 18, 2019 | Christopher Christie became a director |
| Aug 16, 2019 | Kristen Williams listed as Chief Administrative Officer (previously CAO and General Counsel) in SEC filings |
| Jun 19, 2019 | Max Reinhardt became President |
| Aug 29, 2018 | Roy Winston became Chief Clinical Officer |
| Aug 29, 2018 | Dennis McLoughlin became Chief Commercial Officer |
| Jun 13, 2018 | Charles Anthony Laranjeira became SVP, Technical Operations |
| Jun 14, 2017 | Richard Scranton became Chief Scientific Officer |
| Jun 14, 2017 | Mark Froimson became a director |
Not reported recently (16)
- Daryl Gaugler · Last reported as Chief Operating Officer in an SEC filing dated Jan 6, 2025
- Roy Winston · Last reported as Chief Medical Officer in an SEC filing dated Aug 4, 2023
- Dennis McLoughlin · Last reported as Chief Customer Officer in an SEC filing dated Jun 7, 2023
- Max Reinhardt · Last reported as President, Rest of World in an SEC filing dated Jun 7, 2023
- Anthony Molloy · Last reported as Chief Lgl & Compliance Officer in an SEC filing dated Jun 7, 2023
- Ronald J. Ellis Jr. · Last reported as Chief Strategy Officer in an SEC filing dated Jun 7, 2023
- Charles Anthony Laranjeira · Last reported as Chief Technical Officer in an SEC filing dated Jun 16, 2022
- Andreas Wicki · Last reported as a director in an SEC filing dated Jun 7, 2022
- John P Phd Longenecker · Last reported as a director in an SEC filing dated Mar 7, 2022
- Donald C. Manning · Last reported as Chief Medical Officer in an SEC filing dated Jun 11, 2021
- Richard Scranton · Last reported as Chief Scientific Officer in an SEC filing dated Nov 12, 2019
- Robert J. Weiland · Last reported as Chief Commercial Officer in an SEC filing dated Jun 6, 2018
- Scott Braunstein · Last reported as SVP, Strategy & Corp. Dev. in an SEC filing dated Jan 5, 2018
- James B Jones · Last reported as SVP & Chief Medical Officer in an SEC filing dated Nov 20, 2017
- Dennis L Winger · Last reported as a director in an SEC filing dated Jun 16, 2017
- James S Scibetta · Last reported as President in an SEC filing dated Jun 7, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
PCRX Proposed Insider Sales (Form 144)
Latest: 2026-10-08
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
2 filings
· $289K notice value
· 2 unique filers
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
RIKER LAUREN (1, $218K) · SLONIN JONATHAN (1, $71K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-10-08 | RIKER LAUREN | Officer | 6,000 | $217.9K | 2026-10-08 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-08-17 | SLONIN JONATHAN | Officer | 3,040 | $70.6K | 2026-08-17 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-06-12 | Ceesay Abraham | Director | 9,039 | $210.4K | 2026-06-12 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-06-11 | RIKER LAUREN | Officer | 6,115 | $143.7K | 2026-06-11 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-06-04 | WILLIAMS KRISTEN | Officer | 10,259 | $228.5K | 2026-06-04 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-04-23 | Cross Shawn | Officer | 12,941 | $325.6K | 2026-04-23 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-04-22 | Cross Shawn | Officer | 1,500 | $37.5K | 2026-04-22 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-04-21 | Cross Shawn | Officer | 2,845 | $71.1K | 2026-04-21 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-04-20 | Cross Shawn | Officer | 7,714 | $193.9K | 2026-04-20 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-03-17 | Froimson Mark | Director | 500 | $10.9K | 2026-03-17 | Fidelity Brokerage Services LLC | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-05
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Event | Link |
|---|---|---|
| 2026-11-05 | Regulation FD disclosure | EDGAR |
| 2026-10-08 | Material agreement · Regulation FD disclosure | EDGAR |
| 2026-08-04 | Earnings results | EDGAR |
| 2026-06-30 | Material agreement · Regulation FD disclosure | EDGAR |
| 2026-06-11 | Director or officer change · Shareholder vote results · Other events | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
99 ETFs hold PCRX
25 shown · $359.88M total exposure · 0.09% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | IJR iShares Core S&P Small-Cap ETF | iShares (BlackRock) | 0.08% | $87.9M | $103.8B | 2026-11-06 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.05% | $37.7M | $76.6B | 2026-11-06 |
| 3 | AVUV Avantis U.S. Small Cap Value ETF | Avantis | 0.11% | $34.5M | $31.6B | 2026-11-05 |
| 4 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $28.5M | — | 2026-09-30 |
| 5 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.01% | $20.2M | — | 2026-09-30 |
| 6 | SPSM State Street® SPDR® Portfolio S&P 600™ Small Cap ETF | SPDR (State Street) | 0.08% | $13.3M | $15.7B | 2026-11-05 |
| 7 | VBR Vanguard Morningstar Small-Cap Value ETF | Vanguard | 0.02% | $13.2M | — | 2026-09-30 |
| 8 | IJT iShares S&P Small-Cap 600 Growth ETF | iShares (BlackRock) | 0.18% | $13.1M | $7.3B | 2026-11-06 |
| 9 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.09% | $12.6M | $13.9B | 2026-11-06 |
| 10 | XPH State Street® SPDR® S&P® Pharmaceuticals ETF | SPDR (State Street) | 2.69% | $12.6M | $466.5M | 2026-11-05 |
| 11 | VXF Vanguard Extended Market ETF | Vanguard | 0.01% | $11.2M | — | 2026-09-30 |
| 12 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.14% | $9.3M | $6.6B | 2026-11-05 |
| 13 | DFSV Dimensional US Small Cap Value ETF | Dimensional | 0.03% | $8.6M | — | 2026-11-05 |
| 14 | SLYG State Street® SPDR® S&P 600™ Small Cap Growth ETF | SPDR (State Street) | 0.18% | $8.2M | $4.6B | 2026-11-05 |
| 15 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.03% | $5.8M | — | 2026-09-30 |
| 16 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.01% | $5.4M | — | 2026-11-05 |
| 17 | CALF Pacer US Small Cap Cash Cows 100 ETF | Nport | 0.15% | $5.4M | — | 2026-07-31 |
| 18 | BSVO EA Bridgeway Omni Small-Cap Value ETF | Nport | 0.21% | $5.1M | — | 2026-06-30 |
| 19 | IHE iShares U.S. Pharmaceuticals ETF | iShares (BlackRock) | 0.31% | $4.9M | $1.7B | 2026-11-06 |
| 20 | FNDA Schwab Fundamental U.S. Small Company ETF | Nport | 0.05% | $4.9M | — | 2026-08-31 |
| 21 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.02% | $4.8M | — | 2026-08-31 |
| 22 | VIOO Vanguard S&P Small-Cap 600 ETF | Vanguard | 0.06% | $3.5M | — | 2026-09-30 |
| 23 | FSMD Fidelity Small-Mid Multifactor ETF | Fidelity | 0.14% | $3.4M | $2.4B | 2026-11-05 |
| 24 | SFLO VictoryShares Small Cap Free Cash Flow ETF | Nport | 0.49% | $3.0M | — | 2026-06-30 |
| 25 | VHT Vanguard Health Care ETF | Vanguard | 0.01% | $2.8M | — | 2026-09-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
104.16
TTM Diluted EPS
$0.35
TTM Revenue
$746.16M
TTM Net Income
$14.64M
TTM Op. Cash Flow
$187.66M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $192.40M | $4.65M | $0.12 | $57.46M |
| Q1 '26 | 2026-03-31 | $177.38M | $2.92M | $0.07 | $25.68M |
| Q4 '25 | 2025-12-31 | $196.87M | $1.64M | $0.04 | $43.69M |
| Q3 '25 | 2025-09-30 | $179.52M | $5.43M | $0.12 | $60.83M |
| Q2 '25 | 2025-06-30 | $181.10M | $-4.85M | $-0.11 | $12.01M |
| Q1 '25 | 2025-03-31 | $168.92M | $4.81M | $0.10 | $35.46M |
| Q4 '24 | 2024-12-31 | $187.25M | $16.04M | $0.35 | $33.13M |
| Q3 '24 | 2024-09-30 | $168.57M | $-143.47M | $-3.11 | $53.92M |
| Q2 '24 | 2024-06-30 | $178.02M | $18.89M | $0.39 | $53.24M |
| Q1 '24 | 2024-03-31 | $167.12M | $8.98M | $0.19 | $49.10M |
| Q4 '23 | 2023-12-31 | $181.24M | $24.87M | $0.52 | $47.16M |
| Q3 '23 | 2023-09-30 | $163.93M | $10.86M | $0.23 | $41.65M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-04
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
104.16
P/B
2.32
P/S
2.09
EV/EBITDA
16.21
EV/Sales
2.30
ROE
2.2%
ROA
1.2%
Div Yield
0.00%
FCF Yield
12.06%
Debt/Equity
0.54
Current Ratio
—
Market Cap
$1.56B
as of 2026-11-09
PCRX vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| LLY Eli Lilly & Co. | $1.21T | 46.0 | +45.5% | +31.3% | 27 |
| JNJ Johnson & Johnson | $664.9B | 42.9 | +7.8% | +36.2% | 58 |
| VTRS Viatris Inc. Common Stock | $22.8B | — | +4.3% | +64.5% | 43 |
| AMRX Amneal Pharmaceuticals, Inc. Class A Com | $7.0B | 43.4 | +9.3% | +68.0% | 33 |
| LGND Ligand Pharmaceuticals Inc. | $6.1B | 142.3 | +1.0% | +65.4% | 43 |
| OGN Organon & Co. | $3.6B | 18.0 | −3.2% | +91.6% | 19 |
| XERS Xeris Biopharma Holdings, Inc. Common St | $2.8B | — | +38.4% | +114.7% | 15 |
| SUPN Supernus, Inc. Common Stock | $1.5B | — | +26.9% | −44.0% | 11 |
| PCRX Pacira BioSciences, Inc. Common Stock | $1.5B | 104.2 | +5.7% | +49.1% | 67 |
| Peer median | $6.6B | 43.4 | +8.6% | +65.0% | 30 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
4.26M
SI % of Float
11.16%
Days to Cover
1.08
Short Vol Ratio
23.8%
Free Float
38.17M
Float %
95.8%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-09-22